Introduction: Liver and intrahepatic biliary tract cancer primarily includes hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Hepatocellular carcinoma is the most common liver tumor and originates from hepatocytes, usually in the context of cirrhosis or viral infections (hepatitis B and C). Intrahepatic cholangiocarcinoma arises from the bile ducts within the liver and is associated with inflammatory diseases of the biliary tract, such as primary sclerosing cholangitis. Both types tend to be aggressive, with difficult early diagnosis, and treatment may involve surgery, transplantation, ablation, or systemic therapies, depending on the stage of the disease. Objectives: To describe and compare the prevalence of liver and intrahepatic biliary tract cancer across different regions of Brazil from 2015 to 2024. Methods: A quantitative, observational study was conducted with an analysis of the epidemiological profile of liver and biliary tract cancer in the major regions of Brazil between 2015 and 2024. This study was supported by a literature review relevant to the subject. Data were obtained from the Painel-Oncologia-Brasil registry system, available on DATASUS, and population estimates provided by IBGE. Results: Between 2015 and 2024, Brazil recorded 24,360 cases of malignant neoplasms of the liver and intrahepatic bile ducts (ICD-10 C22). The regional distribution shows that the Southeast had the highest absolute number of cases (9,713), followed by the South (6,684), Northeast (4,850), Center-West (1,797), and North (1,316). However, when these figures are related to the estimated population of each region (IBGE, 2024), a more revealing scenario emerges. The South Region, with approximately 30.4 million inhabitants, has the highest proportional case rate, with 21.98 cases per 100,000 inhabitants, significantly higher than more populous regions such as the Southeast (10.84) and Northeast (8.47). Similarly, the North and Center-West, despite similarities in total population, showed different case rates for liver and biliary tract carcinoma, with 7.27 and 10.69 cases per 100,000 inhabitants, respectively. There was a marked increase in the number of cases between 2018 and 2023, peaking in 2023 (3,822 cases), followed by a decrease in 2024. Conclusion: The disparity in case numbers, when compared to the total population of each region, highlights the differences in diagnostic and reporting capabilities among the regions, as well as the possible higher prevalence of risk factors for the development of these pathologies (such as alcohol consumption, obesity, and infectious or metabolic liver diseases). The data suggests a higher relative incidence in economically stronger regions, mainly due to better healthcare system effectiveness, particularly in the Southeast. Meanwhile, the North and Northeast regions may suffer from underreporting, limited access to specialized healthcare, and lower screening coverage.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
